DIRS.INFO The most relevant business & tech news

A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August31, 2023. The U.S. Food and Drug Administration on Wednesday said Eli Lilly (LLY.N) could begin selling its drug tirzepatide for weight loss, making it the second obesity drug in a class known as GLP-1s. Studies of Novo's Wegovy showed that it led to 15% weight loss over 68 weeks, while Lilly's drug, which also targets a second hormone called GIP, demonstrated weight loss of more than 22% over 72 weeks. Drugstore chain Walgreens is seeing "enormous demand" for GLP-1s, said John Driscoll, president, U.S. healthcare at Walgreens Boots Alliance (WBA.O). Much has been made of the impact the new weight loss drugs might have on consumer habits such as snack food purchases, but Driscoll said Walgreens has not seen that yet.

Persons: Victoria Klesty, Eli Lilly, Novo, Novo's Wegovy, Lawrence Tabak, John Driscoll, Tabak, Driscoll, Walgreens, Julie Steenhuuysen, Caroline Stauffer, Deena Beasley, Jamie Freed Organizations: REUTERS, Rights, Reuters, Total Health, U.S . Food, Drug Administration, U.S . National Institutes of Health, Walgreens, Walgreens Boots Alliance, Thomson Locations: Oslo, Norway, August31, Victoria, Chicago, U.S, satiety

☆ NIH to test Pfizer’s Paxlovid, other treatments as potential long Covid therapies
▼ + stars: | 2023-07-31 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

The National Institutes of Health said Monday it launched mid-stage clinical trials to test at least four treatments, including Pfizer 's antiviral Covid-19 pill Paxlovid, as potential therapies for long Covid. But the lack of a specific long Covid treatment pushes some patients to seek unproven – and potentially dangerous – remedies for the condition. "NIH is committed to a highly coordinated and scientifically rigorous approach to find treatments that will provide relief for the millions of people living with long COVID." The NIH will test the safety and effectiveness of the treatments – which include both drugs and medical devices – in groups of 100 to 300 patients with long Covid symptoms. The first part of the phase two trial will test a longer dosing regimen of Paxlovid to see if it improves long Covid symptoms.

Persons: Lawrence Tabak Organizations: National Institutes of Health, Pfizer, Health, NIH

☆ Biden to nominate cancer surgeon Monica Bertagnolli to lead National Institutes of Health
▼ + stars: | 2023-05-15 | by ( Spencer Kimball | ) www.cnbc.com time to read: +1 min

Dr. Monica Bertagnolli speaks during a visit from first lady Jill Biden to the University of California San Francisco Helen Diller Family Comprehensive Cancer Center in San Francisco, Oct. 7, 2022. President Joe Biden will nominate Dr. Monica Bertagnolli, a cancer surgeon, to lead the National Institutes of Health, the White House announced Monday. Bertagnolli is currently the director of the National Cancer Institute and is the first woman to lead the organization. The NIH, which has a budget of about $45 billion, funds medical research across the U.S. and around the world. The agency played a pivotal role in developing the messenger RNA technology that underlies the Covid-19 vaccine made by Moderna.

☆ Biden taps Bertagnolli to lead National Institutes of Health
▼ + stars: | 2023-05-15 | by ( ) www.reuters.com time to read: +1 min

WASHINGTON, May 15 (Reuters) - U.S. President Joe Biden will appoint Monica Bertagnolli, director of the National Cancer Institute, to lead the National Institutes of Health, the White House said on Monday. Bertagnolli will become the second woman to serve as a permanent director of the NIH after a yearlong search to find a permanent replacement for the agency's long-serving leader, Francis Collins. "Dr. Bertagnolli is a world-class physician-scientist whose vision and leadership will ensure NIH continues to be an engine of innovation to improve the health of the American people," Biden said in a statement. Bertagnolli was appointed in October to head the National Cancer Institute, which is a part of NIH, and also served as head of surgical oncology at the Dana-Farber Brigham Cancer Center, one of the nation's top cancer research facilities. Lawrence Tabak has been performing the director duties since December of that year after previously holding the roles of principal deputy director and deputy ethics counselor since 2010 at NIH.

CNN —President Joe Biden will nominate Dr. Monica Bertagnolli, who currently leads the National Cancer Institute, to be the next director of the National Institutes of Health, the White House announced on Monday. Biden called Bertagnolli “a world-class physician-scientist whose vision and leadership will ensure NIH continues to be an engine of innovation to improve the health of the American people,” in a statement Monday. She would lead the country’s medical research agency, overseeing 27 research institutes and centers focused on different areas of medical research, such as cancer, the human genome, as well as allergy and infectious diseases. The nomination to lead NIH marks a fast ascent within the Biden administration for Bertagnolli. In this August 2022 photo, Monica Bertagnolli, newly appointed director of the National Cancer Institute, stands for recognition during remarks by President Joe Biden.

Search resuls for: "Lawrence Tabak"

5 mentions found